Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority revi
Antibody developer Genmab has made a play to boost its expertise in the scalding hot area of antibody-drug conjugates (ADCs), agreeing a $1.8 billion deal to acquire Profo
